Related by context. All words. (Click for frequent words.) 75 randomized #:# 69 weekly subcutaneous injections 69 #mg QD [001] 68 #mg QD [002] 67 8mg/kg 67 pegaptanib 67 relapsed MM 67 intradermal injections 67 mg QD 67 APTIVUS r 67 randomized 66 unresectable stage 66 saline placebo 66 4mg/kg 66 ribavirin RBV 66 ACTEMRA TM 66 desvenlafaxine succinate 66 dose titration 66 HCV RESPOND 2 66 #mg BID [003] 66 tenofovir emtricitabine 66 de novo kidney transplant 65 multicenter Phase III 65 stage IIIB 65 ascending dose 65 label dose titration 65 recurrent glioblastoma multiforme 65 stage IIIb IV 65 treatment naive genotype 65 certolizumab 65 dose escalation phase 65 active comparator 65 #mg BID [001] 65 ritonavir boosted 65 mitoxantrone plus 65 antiretroviral naïve 65 telaprevir dosing 65 #mg ATC 65 double blinded placebo 65 daily subcutaneous injections 65 eosinophilic asthma 65 peginterferon alfa 2b 64 dose escalation clinical 64 interferon alfa 2a 64 multicenter randomized placebo controlled 64 CLARITY study 64 PREZISTA r 64 VELCADE melphalan 64 continuous intravenous infusion 64 mcg BID 64 comparator arm 64 RRMS patients 64 blinded placebo controlled 64 dosing cohorts 64 multicenter randomized controlled 64 REVIVE Diabetes 64 PEGINTRON TM 64 dosage regimens 64 blinded randomized placebo controlled 64 LEXIVA r 64 galiximab 64 aflibercept VEGF Trap 64 q#h 64 rapid virologic response 64 infliximab monotherapy 64 docetaxel Taxotere ® 64 administered subcutaneously 64 GSK# [001] 63 antiretroviral naive 63 azilsartan medoxomil 63 oral rivaroxaban 63 #mg/m# [001] 63 HCV SPRINT 63 Newly Diagnosed Multiple Myeloma 63 bone marrow reticulin deposition 63 pegylated interferon peg IFN 63 Tarceva TM 63 retinal vein occlusion induced 63 RLAI 63 treatment naïve genotype 63 non splenectomized 63 methotrexate monotherapy 63 Panzem R NCD 63 TDF FTC 63 #mg/m# [002] 63 oral antidiabetic medication 63 blind placebo 63 pegylated interferon alfa 2b 63 EVIZON 63 telaprevir dosed 63 BR.# 63 melphalan prednisone 63 tenecteplase 63 recurrent NSCLC 63 intravenous RSD# 63 nab paclitaxel 63 multicenter Phase II 63 dosing cohort 63 chemoradiation therapy 63 colorectal cancer liver metastases 63 DEB# 63 AIR CF1 63 randomized multicenter 63 Aflibercept 63 Hormone Refractory Prostate Cancer 63 alfa 2a 62 dose regimens 62 trastuzumab Herceptin R 62 gemcitabine carboplatin 62 peg IFN 62 insulin detemir 62 placebo controlled Phase III 62 inhalations twice 62 BRIM2 62 Pegasys plus Copegus 62 irbesartan 62 evaluating REVLIMID 62 unresectable HCC 62 mg subcutaneously 62 cilengitide 62 PEG IFN 62 pegylated interferon alfa 2a 62 CIMZIA R 62 dirucotide MBP# 62 receiving highly emetogenic 62 Platinol ® cisplatin 62 OMS# 62 ug dose 62 Capesaris 62 mg Pycnogenol 62 R lenalidomide 62 weekly intravenous infusions 62 metastatic colorectal carcinoma 62 colesevelam HCl 62 dose dose escalation 62 decompensated liver disease 62 CIMZIA TM certolizumab pegol 62 multicenter placebo controlled 62 plus methotrexate 62 phase IIb clinical 62 Phase IIIb 62 placebo controlled clinical 62 ascending doses 62 Anti VEGF 62 prospective multicenter randomized 62 Acute Ischemic Stroke 62 IV NSCLC 62 naïve HCV 62 primary hypercholesterolemia 62 metastatic malignant melanoma 62 #mg/day [001] 62 subcutaneous injections 62 Plicera 62 olmesartan 62 prospective randomized placebo 62 calcineurin inhibitor 62 salmeterol fluticasone 62 MADIT II 62 prospective randomized multicenter 62 budesonide pMDI 62 mg q#h 62 low dose cytarabine 62 adjunctive placebo 62 GAMMAGARD 62 mcg doses 62 mcg QD 62 mg BID 62 Dacogen injection 62 randomized Phase IIb 62 golimumab CNTO 62 AGILECT R 62 flutamide 62 phase IIa 62 atazanavir ritonavir 62 INVEGA ® 62 somatostatin analog 62 Initiate Phase 62 TO AVOID PREGNANCY WHILE 62 lopinavir r 62 headache nasopharyngitis 62 mg kg dose 62 Fludara 62 oral methylnaltrexone 62 immunomodulatory therapy 61 refractory CLL 61 relapsed refractory ALL 61 5mg/kg 61 Aptivus ® 61 PEG INTRON R 61 ® lenalidomide 61 doxorubicin cyclophosphamide 61 relapsed refractory multiple myeloma 61 sunitinib Sutent 61 HGS ETR1 mapatumumab 61 placebo controlled clinical trials 61 receptor tyrosine kinase inhibitor 61 genotypic resistance 61 baminercept 61 Phase #b/#a trial 61 Phase Ib clinical 61 HBeAg negative patients 61 INFERGEN 61 Clinical Trial Evaluating 61 plus COPEGUS 61 abacavir lamivudine 61 squalamine 61 Castration Resistant Prostate Cancer 61 CIMZIA TM 61 multicenter multinational 61 Xelox 61 mcg kg 61 Pegylated Interferon 61 FOLFIRI alone 61 symptomatic BPH 61 IV tPA 61 NATRECOR R 61 Phase IIIb clinical 61 acetonide FA 61 TMC# C# 61 anthracycline containing 61 blind multicenter 61 ancrod 61 relapsing multiple sclerosis 61 prokinetic agent 61 virologic failure 61 MIRAPEX 61 concomitant cardiac 61 metastatic GIST 61 interferon ribavirin 61 TAXOTERE R 61 REVLIMID lenalidomide 61 CYT# potent vascular disrupting 61 miconazole Lauriad ® 61 recurrent malignant glioma 61 Multiple Ascending Dose 61 catheter occlusion 61 naive HCV 61 Traficet EN 61 Retisert TM 61 relapsing remitting MS RRMS 61 dacarbazine 61 haematologic 61 prior chemotherapy regimens 61 adjuvant cisplatin 61 Cutaneous T 61 refractory colorectal cancer 61 rt PA 61 EURIDIS 61 concurrent chemoradiation 61 metastatic renal cell carcinoma 61 venlafaxine ER 61 Torisel 61 fosbretabulin 61 ALT flares 61 interferon gamma 1b 61 #mg q8h 61 placebo PBO 61 randomized multicentre 61 SPRYCEL ® 61 achieved ACR# 61 rilpivirine 61 urocortin 2 61 NLX P# 61 intravenous bolus 61 pegylated interferon alpha 61 unfractionated heparin UFH 61 ATACAND 61 intravitreal injection 61 anemia neutropenia 61 Teriflunomide 61 riociguat 61 clevidipine 61 FOLFOX4 61 forodesine 61 dose cohort 61 Stage IIIb 61 phase Ib 61 prospectively stratified 61 microgram kg 61 NOXAFIL Oral Suspension 61 phase IIIb 61 MGd 61 5-FU/LV 61 estramustine 61 plus prednisone 61 subcutaneous SC 61 intermittent dosing 61 GW# [003] 61 injected subcutaneously 61 mg ustekinumab 61 mg/m2 administered 60 CAELYX 60 rilonacept 60 mapatumumab 60 Pivotal Phase III 60 mcg albinterferon alfa 2b 60 carboplatin paclitaxel 60 motesanib 60 induced macular edema 60 refractory NSCLC 60 dasatinib Sprycel ® 60 vapreotide acetate 60 plus dexamethasone 60 multicenter Phase 60 ORENCIA ® 60 unresectable malignant mesothelioma UMM 60 Relapsed Multiple Myeloma 60 double blinded randomized 60 inhaled tobramycin 60 abiraterone acetate 60 Phase Ib IIa 60 mcg Albuferon 60 subcutaneously administered 60 hereditary deficiency 60 CALGB # [002] 60 triamcinolone 60 placebo controlled Phase 60 vicriviroc 60 tenofovir FTC 60 verteporfin 60 mg eq 60 generation purine nucleoside 60 abatacept 60 Allovectin 7 ® 60 randomized blinded 60 #mg/kg [002] 60 nadroparin 60 multicenter randomized double 60 pharmacokinetic PK study 60 bolus injection 60 #mg BID [002] 60 Randomised 60 FOLFOX6 chemotherapy regimen 60 placebo intravenously 60 goserelin 60 MIRAPEX ER 60 IOP lowering 60 EGFR TKI 60 Cladribine tablets 60 overactive bladder syndrome 60 IMPACT DCM trial 60 placebo dexamethasone 60 plus gemcitabine 60 anthracycline chemotherapy 60 placebo controlled dose escalation 60 IFN alfa 60 nonrandomized 60 olanzapine LAI 60 Peg IFN 60 BARACLUDE ® 60 completely resected 60 metformin sulfonylurea 60 relapsed CLL 60 serum phosphorous 60 PREZISTA ritonavir 60 Neovascular AMD 60 prednisone prednisolone plus 60 ibandronate 60 LPV r 60 cisplatin vinorelbine 60 recurrent glioblastoma 60 oral levofloxacin 60 FOLPI 60 Pemetrexed 60 MIRCERA 60 opioid naive 60 Recurrent Glioblastoma 60 lenalidomide dexamethasone 60 lenalidomide Revlimid R 60 Neupro R 60 mg administered orally 60 anthracycline taxane 60 valopicitabine 60 Relapsed Refractory 60 insulin glulisine 60 mg FV 60 nonmetastatic prostate cancer 60 superficial bladder cancer 60 Investigational Oral 60 AMEVIVE 60 moderate renal impairment 60 BoNTA 60 piperacillin tazobactam 60 buprenorphine implants 60 TORISEL 60 remission induction 60 3mg/kg 60 achieved CCyR 60 doxorubicin docetaxel 60 MAGE A3 ASCI 60 Pegasys ® 60 recurrent GBM 60 multicenter prospective 60 CML CP 60 Folfox 60 multicenter randomized 60 tapentadol ER 60 rALLy 60 mg subcutaneous 60 VICTOR E1 60 AVOREN 60 Pharmacokinetics PK 60 Thrombolysis 60 LHRH receptor positive 60 ritonavir boosted atazanavir 60 Helicobacter pylori eradication 60 Pivotal Trial 60 CHAMPION PCI 60 assessing T DM1 60 ritonavir boosted protease inhibitor 60 concomitant medications 60 tipranavir r 60 adriamycin 60 subconjunctival injection 60 Adjunctive Therapy 60 label multicenter 60 mometasone furoate 60 Flu Cy 60 DU #b 60 docetaxel chemotherapy 60 FUSILEV enhances 60 Metastatic Prostate Cancer 60 YONDELIS 60 5 fluorouracil leucovorin 60 visilizumab 60 adefovir dipivoxil 60 multicentre randomized 60 peginterferon alfa 2a Pegasys 60 Taxotere ® 60 neoadjuvant 60 ongoing Phase 1b 60 Aryplase 60 humanized interleukin 6 60 FOLFOX6 60 CLL SLL 60 Ceplene/IL-2 60 lintuzumab SGN 60 sirolimus eluting stents 60 registrational Phase 60 peginterferon alfa 60 darunavir r 60 pamidronate 60 undetectable HBV DNA 60 phase IIa clinical 60 PEGylated interferon beta 1a 60 denileukin diftitox 60 OvaRex ® MAb 60 APTIVUS ritonavir 60 palifermin 60 paclitaxel poliglumex 60 Myelodysplastic Syndrome MDS 60 IMPACT DCM clinical 60 Decitabine 60 mg/m2 dose 60 HBeAg positive 60 intravitreal injections 60 PegIFN 60 prospective multicenter 60 severe neutropenia 60 Acute Coronary Syndromes ACS 60 ribavirin therapy 60 antibody MAb 60 Randomized Phase 59 pegylated alpha interferon 59 plus prednisone prednisolone 59 phase IIb study 59 tolterodine ER 59 interferon alfa 2b 59 investigational protease inhibitor 59 label dose escalation 59 mRCC 59 chemotherapy cisplatin 59 mg/m2 cohort 59 severe hypercholesterolemia 59 intravitreal insert 59 otamixaban 59 AZILECT R 59 Phase Ib II 59 dexamethasone Decadron 59 metastatic HRPC 59 known sulfonamide allergy 59 CUSTOM III 59 novel VDA molecule 59 stage IIIb 59 postoperative chemotherapy 59 6 mercaptopurine 59 Initiated Phase 59 adalimumab 59 oxymorphone ER 59 thorough QT 59 NSABP B 59 virologically suppressed 59 mild renal insufficiency 59 CsA 59 intravitreal triamcinolone 59 Phase III placebo controlled 59 trials RCTs 59 Hypertensive adverse reactions 59 achieve sustained virologic 59 Lucentis monotherapy 59 relapsed myeloma 59 heavily pretreated 59 hoFH 59 Cloretazine R VNP#M 59 receiving VELCADE 59 volociximab 59 dalteparin 59 #I TM# 59 Granted Orphan Drug 59 erlotinib Tarceva ® 59 evaluating mipomersen 59 Budesonide foam crofelemer 59 unresectable locally advanced 59 relapsed AML 59 Ozarelix 59 maximally tolerated dose 59 biliary tract cancer 59 neovascular form 59 ARB telmisartan 59 aspirin clopidogrel 59 mg qd 59 anagrelide 59 #:# randomization 59 canakinumab 59 Phase III multicenter 59 blinded placebo 59 morphometric vertebral fractures 59 intravenous REOLYSIN 59 MVax 59 dose escalation 59 Meets Primary Endpoint 59 Severe Sepsis 59 cyclophosphamide chemotherapy 59 microbiologically evaluable 59 CHOP chemotherapy 59 advanced medullary thyroid 59 Initiates Phase III 59 Amrubicin 59 celgosivir 59 sirolimus eluting stent 59 intra articular injection 59 painful diabetic neuropathy 59 SIMPADICO 59 docetaxel Taxotere R 59 Phase III randomized controlled 59 SinuNase TM 59 macular edema secondary 59 Cloretazine 59 mg/# hr 59 apremilast 59 divalproex sodium 59 Patients Treated With 59 timepoints 59 events AEs 59 evaluable 59 QTcF 59 alpha 2a 59 refractory metastatic 59 metastatic castrate resistant 59 Hepatocellular Carcinoma HCC 59 FOLFOX 59 Oral Fingolimod 59 taxane resistant 59 subcutaneous PRO 59 mitoxantrone 59 budesonide foam 59 Romidepsin 59 Multicenter 59 REYATAZ r arm 59 achieved statistical significance 59 R# #mg BID 59 adjuvant colon cancer 59 refractory metastatic colorectal cancer 59 Proellex TM 59 nasopharyngitis headache 59 Zemplar Capsules 59 develop HBV reactivation 59 dopamine partial agonist 59 oral prednisone 59 NOX E# 59 Phase III confirmatory 59 Monotherapy 59 INSPIRE Trial Phase III 59 demonstrated antitumor activity 59 progression TTP 59 refractory chronic lymphocytic 59 Raptiva r 59 mg RDEA# 59 IBS C 59 cardiovascular calcification 59 HBeAg negative 59 AZOR 59 ritonavir boosted lopinavir 59 Endarterectomy 59 APTIVUS 59 Contrave# 59 q8h 59 FOLFIRI 59 REMICADE ® 59 KRAS mutations occur 59 saquinavir ritonavir 59 ZYBRESTAT fosbretabulin 59 Myocardial Infarction Study 59 confirmatory Phase III 59 evaluating tivozanib 59 REVLIMID ® 59 APEX PD 59 Targretin capsules 59 zoledronic acid Reclast 59 undetectable HCV RNA 59 metaglidasen 59 CorVue ™ 59 adjunctive ABILIFY 59 Free Survival PFS 59 underwent surgical resection 59 Investigational Treatment 59 milrinone 59 Trobalt 59 randomized controlled multicenter 59 Randomized Phase II 59 Naive Patients 59 masked placebo controlled 59 placebo controlled 59 STELARA TM 59 OvaRex MAb 59 Sapacitabine 59 maximally tolerated lipid lowering 59 nonmetastatic 59 via intradermal injections 59 Intravitreal 59 initiate Phase IIa 59 aplindore 59 rheumatoid arthritis psoriatic arthritis 59 PROMACTA 59 zonisamide SR 59 rFSH 59 tinzaparin 59 randomized multicenter trial 59 patientswith 59 Glatiramer Acetate 59 placebo controlled randomized 59 ocular hypertension 59 μg dose 59 DCVax ® Brain 59 intravenous dosing 59 ALN VSP Phase 59 oral ribavirin 59 Sutent sunitinib 59 BZA CE 59 Primary endpoints 59 vidofludimus 59 unresectable Stage III 59 temsirolimus 59 periodically reassessed 59 pharmacokinetic parameters 59 myelodysplastic myeloproliferative diseases 59 fluoropyrimidine 59 vinorelbine 59 caspofungin 59 adalimumab Humira 59 achieved sustained virologic 59 pregabalin Lyrica 59 Anturol TM 59 HBeAg + 59 REYATAZ r 59 unstable angina UA 59 urate lowering 59 topical testosterone 59 PASI scores 59 lopinavir ritonavir plus 59 clodronate 58 trastuzumab Herceptin ® 58 idarubicin 58 pegylated interferon alpha 2a 58 Dementia Related Psychosis 58 anastrazole 58 prospectively defined 58 nadolol 58 randomized Phase 2b 58 oral antidiabetic agents 58 Phase 2b randomized 58 bendamustine 58 Fludara ® 58 dapagliflozin plus 58 BENICAR HCT 58 MKC# MT 58 venlafaxine XR 58 acyclovir Lauriad R 58 darunavir ritonavir 58 acupuncture sham acupuncture 58 esophageal candidiasis 58 tocilizumab 58 SUSTENNA TM 58 LATUDA 58 blinded randomized 58 Navelbine ® 58 paclitaxel Taxol R 58 glycoprotein IIb IIIa inhibitor 58 HIV coinfected 58 mg TID 58 nilotinib Tasigna ® 58 Diabetic Macular Edema 58 dacarbazine DTIC 58 Phase IIa trials 58 Phase #/#a 58 Zyclara 58 SYN# 58 multidose 58 oropharyngeal candidiasis OPC 58 rALLy clinical trial 58 TELINTRA 58 dacarbazine chemotherapy 58 p# MAP kinase inhibitor 58 symptomatic paroxysmal AF 58 anthracyclines taxanes 58 Peginterferon Alfa 2a 58 oral nucleoside analogue 58 ASCT 58 Phase Ib study 58 Phase IIb III 58 Mycophenolate Mofetil 58 randomized controlled Phase 58 GLP1 agonist 58 paricalcitol 58 Adjuvant Treatment 58 colorectal liver metastases 58 unblinded 58 rFVIIa 58 thalidomide Thalomid 58 Renal Impairment 58 EchoCRT 58 dosed orally 58 plus ribavirin 58 RSD# oral 58 TELINTRA R 58 nicardipine 58 histologically confirmed 58 neratinib 58 Phase 2b Clinical Trial 58 MIST II 58 REMINYL ® 58 Relapsing Remitting Multiple Sclerosis 58 vandetanib 58 GetGoal Phase III 58 resectable pancreatic cancer 58 EXPLORE Xa 58 achieved PASI 58 pyridostigmine 58 nucleoside analog 58 O PPDS 58 prospectively randomized 58 DSMB recommended 58 fluticasone furoate 58 bupropion SR 58 CANCIDAS 58 metastatic hormone refractory 58 label multicenter Phase 58 beclomethasone dipropionate 58 omega interferon 58 Elitek 58 teriflunomide 58 atypical Hemolytic Uremic Syndrome 58 Lodotra TM 58 evaluating picoplatin 58 deferoxamine 58 Perceiva 58 log# IU mL 58 refractory CTCL 58 Simulect 58 idursulfase 58 Heterozygous Familial Hypercholesterolemia 58 IFN α 58 TASKi3 58 antiepileptics 58 multicentre randomized double 58 icatibant 58 FOR FURTHER INFORMATION ABOUT 58 FOLFOX chemotherapy 58 cediranib 58 EVIZON TM 58 ceftazidime 58 pyrimidine nucleoside analog 58 uremic pruritus 58 peg interferon 58 cisplatin gemcitabine 58 dose escalation Phase 58 DOXIL 58 Initiates Phase II 58 receiving XGEVA 58 PD LID 58 Testosterone MDTS ® 58 6R BH4 58 events TEAEs 58 R entecavir 58 monotherapy 58 XL# SAR# 58 Vidaza azacitidine 58 Phase III randomized 58 Androxal TM 58 null responder HCV 58 Kepivance 58 metastatic CRPC 58 subcutaneous dosing 58 VFEND 58 FIRMAGON 58 dose cohorts 58 RhuDex R 58 LymphoStat B belimumab 58 COU AA 58 evaluable subjects 58 bepotastine besilate nasal spray 58 Apidra ® 58 systemic ALCL 58 albiglutide 58 imatinib therapy 58 Secondary efficacy endpoints 58 zolmitriptan 58 ZACTIMA 58 IMPACT DCM 58 CRLX# 58 either acutely decompensated 58 castrate resistant prostate cancer 58 Major Depressive Disorder MDD 58 MAXY alpha 58 mitoxantrone chemotherapy 58 underwent liver transplantation 58 oral ridaforolimus 58 paclitaxel cisplatin 58 inhaled treprostinil 58 administered intranasally 58 oral vancomycin 58 Perforomist Inhalation Solution 58 alkylating agent 58 alefacept 58 beta 1a 58 multicentre randomized controlled 58 recurrent metastatic ovarian cancer 58 antithymocyte globulin 58 citalopram hydrobromide 58 CRp 58 ABC/3TC 58 ELOXATIN 58 mg kg BID 58 subcutaneous formulation 58 R rilonacept Injection 58 mecasermin 58 Vincristine 58 Gabapentin GR 58 Study Evaluating 58 COSIRA trial 58 lanthanum carbonate 58 timolol 58 EGFR expressing mCRC 58 PREZISTA rtv 58 urinary N telopeptide 58 Multicenter Randomized Double 58 NRTI backbone 58 EDEMA3 58 AKT inhibitor 58 Known hypersensitivity 58 TTF Therapy 58 severe exacerbations 58 SCH # 58 vinorelbine tartrate 58 tipranavir ritonavir 58 OZURDEX ® 58 Triapine 58 HCV Genotype 58 SCIg 58 GOUT 58 #mg/#mg 58 Peginterferon 58 Pegylated Liposomal Doxorubicin 58 acute peripheral arterial 58 Zavesca ® 58 sunitinib 58 biologic DMARD 58 peginterferon 58 IV melanoma 58 COREG 58 PegIntron 58 fistulizing Crohn disease 58 TLK# 58 Brinavess 58 preoperative radiotherapy 58 postmenopausal osteoporotic women 58 dose cytarabine 58 genotype 1a 58 glycosylated hemoglobin levels 58 fallopian tube cancers 58 dose escalation trial 58 Randomized Evaluation 58 subcutaneous doses 58 briakinumab 58 concurrent ITP 58 ® natalizumab 58 bortezomib refractory 58 Pivotal Phase 58 non squamous histology 58 paclitaxel carboplatin 58 mycophenolate mofetil MMF 58 viral kinetics 58 acute HAE attacks 58 VIRAMUNE XR 58 elagolix 58 gadobutrol 58 using lactulose concomitantly 58 Telintra 58 achieved sustained virological 58 non squamous NSCLC 58 II Clinical Trial 58 hyperphenylalaninemia HPA due 58 Phase IIIb study 58 GnRH agonist 58 levosimendan 58 underwent resection 58 ZOLINZA 58 Achieves Primary Endpoint 58 mg/m2 IV 58 avosentan 58 metastatic malignant 58 GERD migraine headaches 58 Medullary Thyroid Cancer 58 chemoradiotherapy 58 chlorambucil 58 MACUGEN 58 PROSTVAC VF 58 CIMZIA ™ 58 anakinra 58 advanced metastatic renal 58 FAMPYRA 58 RECORD1 58 multicenter phase 58 mg Lucentis 58 Eliquis 58 hypoxia activated prodrug 58 neutropenia dehydration dyspnea 58 sorafenib tablets 58 headache nausea diarrhea 58 palonosetron 58 Laquinimod 58 oral prodrug 58 SAR# [004] 58 diagnosed GBM 58 sequential dose escalation 58 Octreolin 58 CTA# Injection 58 systemic juvenile idiopathic 58 IIa trial 58 atorvastatin #mg 57 tacrolimus ointment 57 rufinamide 57 dimeglumine 57 plus OBT 57 docetaxel pretreated 57 prospective nonrandomized 57 beta2 agonist 57 Patients Treated 57 LMWH 57 metastatic CRC 57 patients undergoing percutaneous 57 fluticasone salmeterol 57 Diamyd r 57 taxane chemotherapy 57 EOquin TM phase 57 Completes Patient Enrollment 57 Gliadel Wafer 57 oral deforolimus 57 demonstrated clinically meaningful 57 intravitreal 57 everolimus eluting stents 57 TEAEs 57 oral talactoferrin 57 glatiramer acetate 57 metastatic castration resistant 57 REMURA 57 efavirenz EFV 57 BENLYSTA ® 57 recombinant tissue plasminogen 57 Peginterferon alfa 2b 57 Darunavir 57 EDEMA3 trial 57 elevated transaminases 57 AIR2 Trial 57 lopinavir r arm 57 Hsp# Inhibitor 57 orally inhaled migraine 57 LymphoStat B TM 57 Phase 1a clinical 57 recurrent glioma 57 FOLFIRI chemotherapy 57 Phase IIb Trial 57 included conjunctival hemorrhage 57 mg d 57 multiple myeloma MM 57 Refractory Hodgkin Lymphoma 57 smoldering multiple myeloma 57 thrombin inhibiting aptamer 57 Trial Evaluating